Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 4Pain 3Fatigue 3Anxiety Disorders 3Neoplasms 2Vomiting 1Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Nausea 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Caregiver Burden 1Carcinoma, Ovarian Epithelial 1Agnosia 1

Interventions

Carboplatin 158Paclitaxel 152Bevacizumab 85Gemcitabine 48liposomal doxorubicin 47Taxes 47Topotecan 41Cisplatin 34pembrolizumab 33Cyclophosphamide 27olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 20Docetaxel 20Drug Therapy 19Magnetic Resonance Spectroscopy 17niraparib 16Doxorubicin 16Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 13rucaparib 12Nivolumab 12Cytoreduction Surgical Procedures 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Chemotherapy, Adjuvant 9130-nm albumin-bound paclitaxel 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fallopian Tube Neoplasms × Touch × Clear all
NCT00293293 2017-12-28

Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine

Masonic Cancer Center, University of Minnesota

Phase NA Completed
43 enrolled 22 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡